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Abstract
This issue of CytoJournal contains an article on screening for anal intraepithelial neoplasia in high-
risk male patients. This accompanying Editorial focuses on current understanding of this relatively
new disease entity, with insights as to the potential role of screening cytopathology in the
epidemiology, pathophysiology and clinical management of this HIV and HPV related anal lesion,
which predominates in male patients living long-term with AIDS. Mention is made of techniques of
obtaining samples, methods of preparation, and morphologic classification. Issues of anoscopic
confirmation, as well as topical and surgical management are emphasized. The similarity of initial
experiences in anal screening to problems encountered early in cervical cancer screening programs
several decades ago, are highlighted.
Note
For corresponding research article please see Arian et al,
2005 [15]
The subject of anal screening cytology has entered the epi-
demiologic and cytopathologic literature as a topic of
interest over the last decade, and is highlighted in this
issue of CytoJournal in an article by Arain and colleagues.
Until recently, anal cancer was not considered to be a neo-
plasm of major public health concern [1]. It occurred
infrequently, usually in older people, affecting women
more often than men; further, being a neoplasm of low
incidence, it remained under the radar in terms of screen-
ing potential. In some respects, anal cancer mirrored cer-
vical cancer in unscreened women, presenting late in the
course of the disease with a variety of pelvic symptoms,
and having a protracted, ultimately fatal, course. Patients
invariably became social outcasts, suffering from intolera-
ble fecal complications, which presented major nursing
challenges. Two aspects of this scenario have changed.
First was the fairly recent introduction of effective modern
treatment regimes for invasive anal squamous cancers uti-
lizing chemo-radiation, leading to improvement in mor-
bidity and long term survival [2,3]. The second significant
alteration was seen in epidemiology, and this is the area
which has come to involve screening cytopathology.
During the 1990s, in several European and North Ameri-
can cancer centers, an initially unaccountable increase in
anal cancers was seen in younger people. It soon became
apparent that HIV-positive homosexual males were
affected in numbers greatly in excess of those expected.
This was first noted in those urban areas in which large
concentrations of homosexual men had been treated
since the outbreak of the HIV epidemic. The term "males
having sex with males" (MSM) was coined to cover these
high-risk individuals. Preliminary information gleaned
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from screening programs in high HIV-positive incidence
areas amongst MSM, showed detection rates of intraepi-
thelial and early invasive neoplasia higher than any inci-
dence ever recorded for cervical cancer screening. Further,
HIV-negative homosexual MSMs, and HIV positive non-
homosexual men (eg drug users) also exhibited an
increased incidence of pre-malignant and invasive anal
carcinomas. More recently, the syndrome of early onset
anal cancer has been extended to include HIV-positive
female patients, as well as females who are not HIV-posi-
tive, but who have genital HPV. All these groups show a
higher incidence of abnormal anal cytopathology, though
none quite as high as that found in HIV positive MSM.
The unifying factor in most instances is ano-receptive
intercourse, or extension of HPV infection from the geni-
tal tract to the anal mucosa, most obvious in the face of
deficient immunity, or high viral load [4-6].
Epidemiologic studies have indicated that a prolonged
preclinical phase precedes the onset of anal cancer in these
high-risk groups. Just as in the cervix, there is a transi-
tional zone (although not an abrupt squamocolumnar
junction) in the anus. Rectal mucosa, with goblet cells,
ends about one inch proximal to the external sphincter,
giving way to a transitional epithelium, which in turn
blends into a stratified squamous epithelium at the level
of the anus. (External to the anus, any lesions which arise
are considered to be primary skin lesions rather than anal
lesions.) Almost all anal cancers develop in the transi-
tional zone, where atypical, dysplastic and in-situ lesions
are identifiable histologically. The cytologic counterparts
are those of atypical cells of uncertain significance
(ASCUS), low grade squamous intraepithelial lesions
(LSIL) and high grade squamous intraepithelial lesions
(HSIL). Once this natural history had been demonstrated
and confirmed, it seemed natural that exfoliative cytology
could be investigated as an "anal Pap smear" [7,8].
As with the cervix, the technique of obtaining the anal
sample is critical to the success of screening. Standard
colonic preparation is not required, but the rectum should
be emptied prior to obtaining the anal sample. Brushes,
brooms and Dacron swabs have all been used, the type of
spatula probably being less important than the skill of the
operator. The instrument is inserted to a depth of one and
a half inches beyond the external sphincter, and subse-
quently withdrawn in a firm downward spiral movement
incorporating 10–12 rotations, to ensure the device has
made contact with the full surface area of the transforma-
tion zone. Some have used direct smears onto glass slides
with immediate wet fixation; most centers, however,
employ immediate insertion of the scraping device into
liquid fixative for thin layer preparation. This appears
both to improve adequacy and preservation, and also to
eliminate any fecal contamination; residual material in
the vial can be used for HPV studies if required, or for the
creation of a bank of teaching slides.
There has been a relative dearth of literature on the cyto-
morphology of anal samples [9-11]. Classification accord-
ing to Bethesda guidelines has been advised, implying
similarity of the exfoliative cytology of atypical squamous
cells of undetermined significance (ASC-US), anal
intraepithelial lesions (A-SIL) and invasive squamous-cell
neoplasms to those encountered in the cervix. This early
in the development of the science of anal screening, and
evident also in the current article in CytoJournal, there are
indications that cytologic evaluation may not fully antici-
pate the severity of some lesions, when compared with
biopsies taken simultaneously. Several groups have
advised that all abnormal anal Paps should be followed
by anoscopic evaluation, with biopsy confirmation when
necessary. Anoscopy essentially mirrors colposcopy, ena-
bling the viewer to see vascular abnormalities at magnifi-
cation, and direct biopsies to the most abnormal-
appearing areas. Despite these basic similarities, it is
strongly stated in the literature that expertise in colpos-
copy does not equate to immediate competence in anos-
copy; a significant learning curve exists for those wishing
to acquire excellence in anoscopic technique, with associ-
ated accurate biopsy sampling. It is important that the
anoscopist not be sidelined by visible condylomata,
which may merely be sentinels of deeper flat lesions of
higher grade. At the present time, lack of available exper-
tise in this interventional follow-up of abnormal anal
Paps may be the single limiting factor in any new screen-
ing program. It thus behooves those interpreting anal
samples to be as proficient as they can be in pre-interven-
tional assessment of the anal transformation zone.
Experience over the last decade suggests that anal cancer
may be as highly appropriate a target for screening as is
the cervix, in selected populations. The neoplasm is fre-
quently encountered in well-defined high-risk groups. It
has a detectable pre-malignant phase, and is amenable to
easy cytologic sampling. Cytodiagnosis is reasonably sen-
sitive and highly specific, and histologic confirmation is
relatively easily obtained by well-trained personnel. If
there is a current area of deficiency in such programs, it
may well be in the treatment of intraepithelial lesions,
which, as yet, has not been adequately assessed in large
numbers of patients. It is known that highly active anti-
retroviral therapy (HAART) does not appear to alter the
pathophysiology of anal lesions once initiated. A variety
of topical agents such as podophyllotoxin and imiquimod
have been tried, as has intralesional interferon; superficial
ablative therapies including liquid nitrogen, electrocau-
tery, laser and LEEP have been attempted with varying
success rates. Circumferential surgical resection almost
inevitably results in unacceptable loss of sphincter controlPublish with BioMed Central    and   every 
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and soiling, but anoscopy-directed limited excision may
prove less morbid. The fact that so many options are avail-
able implies perhaps that no single modality is yet consid-
ered sufficiently effective, with minimal complication
[12,13]. This, too, is reminiscent of the early years of man-
agement of cervical pre-neoplasia, when a host of meth-
ods was pursued in attempted elimination of focal lesions
of the squamocolumnar junction. As in the cervix, human
ingenuity will undoubtedly prevail, and one or two forms
of extirpation will emerge as both efficacious and uncom-
plicated.
An interesting consideration is whether or not anal cancer,
and thereby anal cytopathology screening programs,
would be of value in the developing world, particularly in
Africa, India and China, where the bulk of the global inci-
dence of HIV resides. This will depend on two very differ-
ent factors. First is the nature of transmission. Unlike the
situation in the developed world, AIDS in these regions is
not essentially a disease of homosexual males; thus, with-
out anal intercourse predominating, an upward trend in
the incidence of anal cancer would seem unlikely. Anal
screening programs would be unnecessary or cost-ineffec-
tive in these communities. The second feature dictating
the institution of screening programs in developing coun-
tries relates to antiretroviral therapy. Anal intraepithelial
neoplasia and cancer are not encountered early in the pro-
gression of HIV/AIDS. Rather, they are late complications
of patients living long-term with AIDS, usually implying
patients living long-term on HAART [14]. Unless afforda-
ble very low cost antiretroviral drugs could be manufac-
tured and distributed widely, it seems unlikely that
patients in developing countries would survive into the
time zone in which delayed neoplasms such as anal can-
cer become a public health priority.
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